Suppr超能文献

适应性突变在前列腺癌细胞抗雄激素耐药中的可能作用。

Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells.

作者信息

Hara Takahito, Kouno Jin, Nakamura Kazuyo, Kusaka Masami, Yamaoka Masuo

机构信息

Pharmacology Research Laboratories I, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka, Japan.

出版信息

Prostate. 2005 Nov 1;65(3):268-75. doi: 10.1002/pros.20282.

Abstract

BACKGROUND

Some mutations of androgen receptor (AR) confer resistance to antiandrogen to prostate cancer (PC) cells. Previously we reported that LNCaP-cxD2 cells established from androgen-dependent LNCaP-FGC PC cells as an antiandrogen bicalutamide-resistant subline harbor W741C/L mutation in the AR gene. In this report, we examined one possible mechanism of the resistance.

METHODS

Change in the gene expression and the protein levels relevant to mutagenesis in LNCaP-FGC cells during bicalutamide-treatment was assessed. The AR sequence of bicalutamide-resistant LNCaP-cxD2 cells was compared with that of parental LNCaP-FGC cells.

RESULTS

The expression of DNA polymerases (Pol) switched from high-fidelity subset to error-prone subset, and DNA mismatch repair proteins (MMR) were down-regulated. The rate of multiple mutations in the AR gene was higher in LNCaP-cxD2 cells than LNCaP-FGC cells.

CONCLUSIONS

These results suggest the hypermutational state might occur in LNCaP-FGC cells during bicalutamide-treatment, which might create the W741C/L mutant AR leading to bicalutamide-resistance.

摘要

背景

雄激素受体(AR)的某些突变赋予前列腺癌(PC)细胞抗雄激素能力。此前我们报道,从雄激素依赖的LNCaP-FGC PC细胞建立的LNCaP-cxD2细胞作为抗雄激素比卡鲁胺耐药亚系,其AR基因存在W741C/L突变。在本报告中,我们研究了一种可能的耐药机制。

方法

评估比卡鲁胺处理期间LNCaP-FGC细胞中与诱变相关的基因表达和蛋白质水平的变化。将比卡鲁胺耐药的LNCaP-cxD2细胞的AR序列与亲本LNCaP-FGC细胞的AR序列进行比较。

结果

DNA聚合酶(Pol)的表达从高保真亚群转变为易出错亚群,DNA错配修复蛋白(MMR)下调。LNCaP-cxD2细胞中AR基因的多重突变率高于LNCaP-FGC细胞。

结论

这些结果表明,在比卡鲁胺处理期间,LNCaP-FGC细胞可能会出现高突变状态,这可能产生导致比卡鲁胺耐药的W741C/L突变型AR。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验